PredictImmune

Announcement

 

It is with a heavy heart that we inform you that we have discontinued development and manufacture of PredictSURE IBD.

PredictImmune, our academic founders, our partners and our investors have worked hard over the last six years to bring PredictSURE IBD to market with the aim of improving patient outcomes.

Unfortunately, these efforts have been unsuccessful, and we have taken the difficult decision to wind down our operations.
We would like to recognise our partners and our clinical and patient advisors and advocates who have supported us for many years. Thank you for the trust you have placed in us.

Whilst our journey may be ending, we remain confident that future advances in prognostic testing, therapeutics and care pathways will improve the lives of those living with inflammatory bowel disease and other chronic immune-mediated diseases. We hope that our research and clinical findings will add to the body of research and will spur future innovation in these areas.

Thank you.
The PredictImmune team

Corporate enquiries: pi.admin@predictimmune.com
Finance enquiries: accounts@predictimmune.com